Linezolid to treat extensively drugresistant TB: Retrospective data are confirmed by experimental evidence

European Respiratory Journal

Volumn 42, Issue 1, 2013, Pages 288-290

  Sotgiu, Giovanni ^a   Centis, Rosella ^b   D'Ambrosio, Lia ^b   Spanevello, Antonio ^c,d   Migliori, Giovanni Battista ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c UNIVERSITY OF INSUBRIA   (Italy)

^d IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID;

ANEMIA; BACTERIUM CULTURE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GASTROINTESTINAL DISEASE; HUMAN; LETTER; LEUKOPENIA; OPTIC NEURITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SPUTUM SMEAR; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ACETAMIDES; ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; MALE; OXAZOLIDINONES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84880167301     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00191712     Document Type: Letter

References (10)

1. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
2. Migliori GB, Zellweger JP, Abubakar I, et al. European Union standards for tuberculosis care. Eur Respir J 2012; 39: 807-819.
3. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
4. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality for multidrugresistant tuberculosis. Eur Respir J 2013; 41: 1393-1400.
5. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380: 986-993.
6. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012; 16: 447-454.
7. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
8. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolidcontaining regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013; 41: 1386-1392.
9. Alsaad N, van Altena R, Pranger AD, et al. Evaluation of co-trimoxazole in treatment of multidrug-resistant tuberculosis. Eur Respir J 2013 [in press DOI: 10.1183/09031936.00114812].
10. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508-1518.